Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system

Seminars in Cancer Biology

Volumn 13, Issue 1, 2003, Pages 59-67

  Scheffner, Martin ^a   Whitaker, Noel J ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cervical cancer; E6 AP; HPV; p53; pRB

Indexed keywords

PROTEASOME; PROTEIN P53; REGULATOR PROTEIN; UBIQUITIN;

CARCINOGENESIS; HUMAN; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN INTERACTION; REVIEW; UTERINE CERVIX CANCER; VIRUS GENE; WART VIRUS;

EID: 0037325976     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-579X(02)00100-1     Document Type: Article

References (86)

1. Hingamp P.M., Arnold J.E., Mayer R.J., Dixon L.K. A ubiquitin conjugating enzyme encoded by African swine fever virus. EMBO J. 11:1992;361-366.
2. Coscoy L., Sanchez D.J., Ganem D. A novel class of herpesvirus-encoded membrane-bound E3 ubiquitin ligases regulates endocytosis of proteins involved in immune recognition. J. Cell Biol. 155:2001;1265-1273.
3. Coscoy L., Ganem D. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc. Natl. Acad. Sci. U.S.A. 97:2000;8051-8056.
4. Ishido S., Wang C., Lee B.S., Cohen G.B., Jung J.U. Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J. Virol. 74:2000;5300-5309.
5. Schubert U., Ott D.E., Chertova E.N., Welker R., Tessmer U., Princiotta M.F.et al. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc. Natl. Acad. Sci. U.S.A. 97:2000;13057-13062.
6. Strack B., Calistri A., Accola M.A., Palu G., Gottlinger H.G. A role for ubiquitin ligase recruitment in retrovirus release. Proc. Natl. Acad. Sci. U.S.A. 97:2000;13063-13068.
7. Patnaik A., Chau V., Wills J.W. Ubiquitin is part of the retrovirus budding machinery. Proc. Natl. Acad. Sci. U.S.A. 97:2000;13069-13074.
8. zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochim. Biophys. Acta. 1288:1996;F55-F78.
9. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. 92:2000;690-698.
10. Mantovani F., Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene. 20:2001;7874-7887.
11. Munger K., Basile J.R., Duensing S., Eichten A., Gonzalez S.L., Grace M.et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene. 20:2001;7888-7898.
12. Lambert P.F., Pan H., Pitot H.C., Liem A., Jackson M., Griep A.E. Epidermal cancer associated with expression of human papillomavirus type 16 E6 and E7 oncogenes in the skin of transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 90:1993;5583-5587.
13. Arbeit J.M., Munger K., Howley P.M., Hanahan D. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J. Virol. 68:1994;4358-4368.
14. Werness B.A., Levine A.J., Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 248:1990;76-79.
15. Dyson N., Howley P.M., Munger K., Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 243:1989;934-937.
16. Dyson N., Guida P., Munger K., Harlow E. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J. Virol. 66:1992;6893-6902.
17. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63:1990;1129-1136.
18. Crook T., Tidy J.A., Vousden K.H. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell. 67:1991;547-556.
19. Scheffner M., Huibregtse J.M., Vierstra R.D., Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 75:1993;495-505.
20. Boyer S.N., Wazer D.E., Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56:1996;4620-4624.
21. Berezutskaya E., Yu B., Morozov A., Raychaudhuri P., Bagchi S. Differential regulation of the pocket domains of the retinoblastoma family proteins by the HPV16 E7 oncoprotein. Cell Growth Diff. 8:1997;1277-1286.
22. Jones D.L., Thompson D.A., Munger K. Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology. 239:1997;97-107.
23. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 12:1998;2245-2262.
24. Thomas J.T., Hubert W.G., Ruesch M.N., Laimins L.A. Human papillomavirus type 31 oncoproteins E6 and E7 are required for the maintenance of episomes during the viral life cycle in normal human keratinocytes. Proc. Natl. Acad. Sci. U.S.A. 96:1999;8449-8454.
25. Flores E.R., Allen-Hoffmann B.L., Lee D., Lambert P.F. The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. J. Virol. 74:2000;6622-6631.
26. Banks L., Edmonds C., Vousden K.H. Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells. Oncogene. 5:1990;1383-1389.
27. Jewers R.J., Hildebrandt P., Ludlow J.W., Kell B., McCance D.J. Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes. J. Virol. 66:1992;1329-1335.
28. Brokaw J.L., Yee C.L., Munger K. A mutational analysis of the amino terminal domain of the human papillomavirus type 16 E7 oncoprotein. Virology. 205:1994;603-607.
29. Ciccolini F., Di Pasquale G., Carlotti F., Crawford L., Tommasino M. Functional studies of E7 proteins from different HPV types. Oncogene. 9:1994;2633-2638.
30. Schmitt A., Harry J.B., Rapp B., Wettstein F.O., Iftner T. Comparison of the properties of the E6 and E7 genes of low- and high-risk cutaneous papillomaviruses reveals strongly transforming and high Rb-binding activity for the E7 protein of the low-risk human papillomavirus type 1. J. Virol. 68:1994;7051-7059.
31. Gonzalez S.L., Stremlau M., He X., Basile J.R., Munger K. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J. Virol. 75:2001;7583-7591.
32. Helt A.M., Galloway D.A. Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J. Virol. 75:2001;6737-6747.
33. Giarre M., Caldeira S., Malanchi I., Ciccolini F., Leao M.J., Tommasino M. Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle arrest. J. Virol. 75:2001;4705-4712.
34. Berezutskaya E., Bagchi S. The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome. J. Biol. Chem. 272:1997;30135-30140.
35. Higashitsuji H., Itoh K., Nagao T., Dawson S., Nonoguchi K., Kido T.et al. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat. Med. 6:2000;96-99.
36. Dawson S., Apcher S., Mee M., Higashitsuji H., Baker R., Uhle S.et al. Gankyrin: an ankyrin-repeat oncoprotein interacts with CDK4 kinase and the S6 ATPase of the 26S proteasome. J. Biol. Chem. 277:2002;10893-10902.
37. Smotkin D., Wettstein F.O. The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein. J. Virol. 61:1987;1686-1689.
38. Reinstein E., Scheffner M., Oren M., Ciechanover A., Schwartz A. Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene. 19:2000;5944-5950.
39. Sellers W.R., Novitch B.G., Miyake S., Heith A., Otterson G.A., Kaye F.J.et al. Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes Dev. 12:1998;95-106.
40. Stubenrauch F., Laimins L.A. Human papillomavirus life cycle: active and latent phases. Semin. Cancer Biol. 9:1999;379-386.
41. Dalal S., Gao Q., Androphy E.J., Band V. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. J. Virol. 70:1996;683-688.
42. Kiyono T., Foster S.A., Koop J.I., McDougall J.K., Galloway D.A., Klingelhutz A.J. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature. 396:1998;84-88.
43. Gao Q., Singh L., Kumar A., Srinivasan S., Wazer D.E., Band V. Human papillomavirus type 16 E6-induced degradation of E6TP1 correlates with its ability to immortalize human mammary epithelial cells. J. Virol. 75:2001;4459-4466.
44. Hainaut P., Hernandez T., Robinson A., Rodriguez-Tome P., Flores T., Hollstein M.et al. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res. 26:1998;205-213.
45. Butz K., Shahabeddin L., Geisen C., Spitkovsky D., Ullmann A., Hoppe-Seyler F. Functional p53 protein in human papillomavirus-positive cancer cells. Oncogene. 10:1995;927-936.
46. Butz K., Geisen C., Ullmann A., Spitkovsky D., Hoppe-Seyler F. Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis. Int. J. Cancer. 68:1996;506-513.
47. Li X., Coffino P. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J. Virol. 70:1996;4509-4516.
48. Elbel M., Carl S., Spaderna S., Iftner T. A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation to their transforming potential. Virology. 239:1997;132-149.
49. Scheffner M., Huibregtse J.M., Vierstra R.D., Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 75:1993;495-505.
50. Scheffner M. Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacol. Ther. 78:1998;129-139.
51. Beer-Romero P., Glass S., Rolfe M. Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells. Oncogene. 14:1997;595-602.
52. Talis A.L., Huibregtse J.M., Howley P.M. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J. Biol. Chem. 273:1998;6439-6445.
53. Hengstermann A., Whitaker N.J., Zimmer D., Zentgraf H., Scheffner M. Characterization of sequence elements involved in p53 stability regulation reveals cell type dependence for p53 degradation. Oncogene. 17:1998;2933-2941.
54. Jiang Y.H., Armstrong D., Albrecht U., Atkins C.M., Noebels J.L., Eichele G.et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron. 21:1998;799-811.
55. Demers G.W., Halbert C.L., Galloway D.A. Elevated wild-type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene. Virology. 198:1994;169-174.
56. Jones D.L., Munger K. Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J. Virol. 71:1997;2905-2912.
57. Hengstermann A., Linares L.K., Ciechanover A., Whitaker N.J., Scheffner M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc. Natl. Acad. Sci. U.S.A. 98:2001;1218-1223.
58. Nevels M., Rubenwolf S., Spruss T., Wolf H., Dobner T. The adenovirus E4orf6 protein can promote E1A/E1B-induced focus formation by interfering with p53 tumor suppressor function. Proc. Natl. Acad. Sci. U.S.A. 94:1997;1206-1211.
59. Querido E., Marcellus R.C., Lai A., Charbonneau R., Teodoro J.G., Ketner G.et al. Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells. J. Virol. 71:1997;3788-3798.
60. Querido E., Blanchette P., Yan Q., Kamura T., Morrison M., Boivin D.et al. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev. 15:2001;3104-3117.
61. Tyers M., Rottapel R. VHL: a very hip ligase. Proc. Natl. Acad. Sci. U.S.A. 96:1999;12230-12232.
62. Huibregtse J.M., Scheffner M., Howley P.M. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 10:1991;4129-4135.
63. Huibregtse J.M., Scheffner M., Howley P.M. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol. Cell Biol. 13:1993;775-784.
64. Huibregtse J.M., Scheffner M., Beaudenon S., Howley P.M. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc. Natl. Acad. Sci. U.S.A. 92:1995;2563-2567.
65. Scheffner M., Nuber U., Huibregtse J.M. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature. 373:1995;81-83.
66. Schwarz S.E., Rosa J.L., Scheffner M. Characterization of human hect domain family members and their interaction with UbcH5 and UbcH7. J. Biol. Chem. 273:1998;12148-12154.
67. Lehman A.L., Nakatsu Y., Ching A., Bronson R.T., Oakey R.J., Keiper-Hrynko N.et al. A very large protein with diverse functional motifs is deficient in rjs (runty, jerky, sterile) mice. Proc. Natl. Acad. Sci. U.S.A. 95:1998;9436-9441.
68. Perry W.L., Hustad C.M., Swing D.A., O'Sullivan T.N., Jenkins N.A., Copeland N.G. The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice. Nat. Genet. 18:1998;143-146.
69. Fang P., Lev-Lehman E., Tsai T.F., Matsuura T., Benton C.S., Sutcliffe J.S.et al. The spectrum of mutations in UBE3A causing Angelman syndrome. Hum. Mol. Genet. 8:1999;129-135.
70. Kumar S., Talis A.L., Howley P.M. Identification of HHR23A as a substrate for E6-associated protein-mediated ubiquitination. J. Biol. Chem. 274:1999;18785-18792.
71. Oda H., Kumar S., Howley P.M. Regulation of the Src family tyrosine kinase Blk through E6AP-mediated ubiquitination. Proc. Natl. Acad. Sci. U.S.A. 96:1999;9557-9562.
72. Thomas M., Banks L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene. 17:1998;2943-2954.
73. Kuhne C., Banks L. E3-ubiquitin ligase/E6-AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G box. J. Biol. Chem. 273:1998;34302-34309.
74. Kao W.H., Beaudenon S.L., Talis A.L., Huibregtse J.M., Howley P.M. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase. J. Virol. 74:2000;6408-6417.
75. Pan H., Griep A.E. Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. Genes Dev. 9:1995;2157-2169.
76. Spitkovsky D., Aengeneyndt F., Braspenning J., von Knebel Doeberitz M. p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene. Oncogene. 13:1996;1027-1035.
77. Thomas M., Banks L. Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J. Gen. Virol. 80:1999;1513-1517.
78. Jackson S., Harwood C., Thomas M., Banks L., Storey A. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev. 14:2000;3065-3073.
79. Bezprozvanny I., Maximov A. PDZ domains: more than just a glue. Proc. Natl. Acad. Sci. U.S.A. 98:2001;787-789.
80. Kiyono T., Hiraiwa A., Fujita M., Hayashi Y., Akiyama T., Ishibashi M. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. U.S.A. 94:1997;11612-11616.
81. Bilder D., Li M., Perrimon N. Cooperative regulation of cell polarity and growth by Drosophila tumor suppressors. Science. 289:2000;113-116.
82. Nakagawa S., Huibregtse J.M. Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol. Cell Biol. 20:2000;8244-8253.
83. Pim D., Thomas M., Javier R., Gardiol D., Banks L. HPV E6 targeted degradation of the discs large protein: evidence for the involvement of a novel ubiquitin ligase. Oncogene. 19:2000;719-725.
84. Pan H., Griep A.E. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes Dev. 8:1994;1285-1299.
85. Song S., Liem A., Miller J.A., Lambert P.F. Human papillomavirus types 16 E6 and E7 contribute differently to carcinogenesis. Virology. 267:2000;141-150.
86. Butz K., Denk C., Ullmann A., Scheffner M., Hoppe-Seyler F. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc. Natl. Acad. Sci. U.S.A. 97:2000;6693-6697.